Following the issue of the draft guidance on 26 October 2023, the company conducted additional analysis and accepted the committees assumptions, updating the value proposition accordingly. This has been reviewed by the Chair of the appraisal committee, who has taken Chair’s action to change the recommendation. Ivosidenib is now recommended, within its marketing authorisation, for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments. As such, the draft guidance has been withdrawn from NICE Docs and the NICE website and final draft guidance will be produced.
The meeting scheduled for 12 December 2023 will not be going ahead.